Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma

Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue

(2014) D. W. Scott et al.   BLOOD

Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

(2014) Matthew J. Maurer et al.   JOURNAL OF CLINICAL ONCOLOGY

Suboptimal dosing of rituximab in male and female patients with DLBCL

(2013) M. Pfreundschuh et al.   BLOOD

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

(2013) Z. Zhou et al.   BLOOD

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial

(2013) Richard Delarue et al.   LANCET ONCOLOGY

Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients

(2012) Stephen M. Ansell et al.   AMERICAN JOURNAL OF HEMATOLOGY

Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B)

(2012) N. Ketterer et al.   ANNALS OF ONCOLOGY

Smartphone and medical related App use among medical students and junior doctors in the United Kingdom (UK): a regional survey

(2012) Karl Frederick Braekkan Payne et al.   BMC Medical Informatics and Decision Making

Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Nathalie A. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma

(2011) I. N. M. Micallef et al.   BLOOD

Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA

(2011) O. Fitoussi et al.   HAEMATOLOGICA

Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma

(2011) Matthew J. Maurer et al.   JOURNAL OF CLINICAL ONCOLOGY

Smartphone App Use Among Medical Providers in ACGME Training Programs

(2011) Orrin I. Franko et al.   JOURNAL OF MEDICAL SYSTEMS

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

(2011) Christian Récher et al.   LANCET

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

(2011) Frédéric Peyrade et al.   LANCET ONCOLOGY

Relapsed/Refractory Diffuse Large B-Cell Lymphoma

(2011) J. W. Friedberg   Hematology-American Society of Hematology Education Program

Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio

(2010) Luis F. Porrata et al.   AMERICAN JOURNAL OF HEMATOLOGY

Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic in

(2010) Ranjana H. Advani et al.   BRITISH JOURNAL OF HAEMATOLOGY

Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma

(2010) Matthew T. Drake et al.   JOURNAL OF CLINICAL ONCOLOGY

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

(2009) K. J. Savage et al.   BLOOD

Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era

(2009) Grzegorz S. Nowakowski et al.   JOURNAL OF CLINICAL ONCOLOGY

Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era

(2008) T. M. Habermann et al.   BLOOD

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study

(2008) Michael Pfreundschuh et al.   LANCET ONCOLOGY